Prevalence and risk factors of hyperuricaemia in non-obese Chinese: a single-centre cross-sectional study by Chengfu Xu, Jinghua Wang, Xinyu Wang, Yishu Chen, Shenghui Chen, Haoliang Zhai

“…Participants with hyperuricaemia showed a higher prevalence of metabolic syndrome and fatty liver disease than participants with normouraemia. …”
Get full text

Evaluation of the Effect of Cichorium intybus L. on the Liver Enzymes in Burn Patients: A Randomized Double-Blind Clinical Trial by Abdolkhalegh Keshavarzi, Rahimeh Akrami, Mohammad M. Zarshenas, Saeid Zareie, Tayyeb Ghadimi, Ali Najafi, Mahsa Rostami Chijan, Azizallah Dehghan, Elham Zarenezhad

“…Some research confirmed that the preparations of the extract are very suitable for the treatment of nonalcoholic fatty liver disease. This is a double-blind randomized controlled clinical trial. …”
Get full text

Risk factors for hepatocellular carcinoma: an umbrella review of systematic review and meta-analysis by Jie Wang, Kaijie Qiu, Songsheng Zhou, Yichao Gan, Keting Jiang, Donghuan Wang, Haibiao Wang

“…Smoking, obesity, non-alcoholic fatty liver disease, diabetes, low platelet, elevated liver enzymes and liver fluke infection increase HCC risk, while coffee consumption, a healthy diet, and bariatric surgery lower it. …”
Get full text

Interface Hepatitis over Grade 2 May Differentiate Chronic Inflammation Associated with CHB from NAFLD in the Early Stage by Yong-fen Zhu, Jin Wang, Jia-zhui Fang, Qiao Yang, Fang-fang Lv

“…Patients with chronic hepatitis B (CHB) concomitant with nonalcoholic fatty liver disease (NAFLD) are increasing. Objectives. …”
Get full text

The AMPK–mTOR Pathway Is Inhibited by Chaihu Shugan Powder, Which Relieves Nonalcoholic Steatohepatitis by Suppressing Autophagic Ferroptosis by Zheng Liang, Dajin Pi, Jianwei Zhen, Haizhen Yan, Chuiyang Zheng, July Liang Chen, Wen Fan, Qingliang Song, Jinyue Pan, Dongdong Liu, Maoxing Pan, Qinhe Yang, Yupei Zhang

“…Nonalcoholic steatohepatitis (NASH) is the advanced stage of nonalcoholic fatty liver disease (NAFLD), which is distinguished by the accumulation of fat in the liver, damage to liver cells, and inflammation. …”
Get full text

Smad4 deficiency in hepatocytes attenuates NAFLD progression via inhibition of lipogenesis and macrophage polarization by Wei Yang, Xuanxuan Yan, Rui Chen, Xin Xin, Shuang Ge, Yongxiang Zhao, Xinlong Yan, Jinhua Zhang

“…Abstract Nonalcoholic fatty liver disease (NAFLD), a major cause of chronic liver disorders, has become a serious public health issue. …”
Get full text

The Effect of Mesenchymal Stem Cell-Derived Exosomes and miR17-5p Inhibitor on Multicellular Liver Fibrosis Microtissues by Farnaz Sani, Mina Soufi Zomorrod, Negar Azarpira, Masoud Soleimani

“…Although several studies have been conducted on modeling human liver disease, it is still challenging to mimic nonalcoholic fatty liver disease in vitro. Here, we aimed to develop a fibrotic liver microtissue composed of hepatocytes, hepatic stellate, and endothelial cells. …”
Get full text

Mouse Models of Nonalcoholic Steatohepatitis: Head-to-Head Comparison of Dietary Models and Impact on Inflammation and Animal Welfare by Andreas Kroh, Vanina Ivanova, Hannah Drescher, Julia Andruszkow, Thomas Longerich, Jochen Nolting, Roman Eickhoff, D. Heise, Karl P. Rheinwalt, Ulf P. Neumann, Florian T. Ulmer

“…The WD represents a model of advanced-stage NASH, and the HFD60 is a strong model of nonalcoholic fatty liver disease (NAFLD) and metabolic syndrome. However, the CAFD should not be considered a NASH model.…”
Get full text

Foxp3 Expression in Liver Correlates with the Degree but Not the Cause of Inflammation by Matthaios Speletas, Nikoletta Argentou, Georgios Germanidis, Themistoclis Vasiliadis, Konstantinos Mantzoukis, Kalliopi Patsiaoura, Pavlos Nikolaidis, Vaios Karanikas, Konstantinos Ritis, Anastasios E. Germenis

“…Liver biopsies obtained from 69 individuals (26 chronic HBV hepatitis, 14 chronic HCV hepatitis, 11 nonalcoholic fatty liver disease, 8 autoimmune diseases, 2 methotrexate-related toxicity, and 8 controls) were examined, by qRT-PCR, for the mRNA expression of Foxp3, IL-10, TGF-β1, Fas, FasL, TRAIL, caspase-3, TNF-α, IFN-γ, and IL-1β. …”
Get full text

Targeted Plasma Bile Acid Metabolomic Analysis in Metabolic Dysfunction-Associated Steatohepatitis and Alcoholic Hepatitis by Yuta Hirata, Yasunaru Sakuma, Hideo Ogiso, Ryozo Nagai, Kenichi Aizawa

“…Child–Pugh score, Fibrosis-4 index, and non-alcoholic fatty liver disease fibrosis score were positively correlated with GCA, whereas the aspartate aminotransferase-to-platelet ratio correlated with TCA, TCDCA, and GCA. …”
Get full text

Unraveling the Beneficial Role of Resveratrol in Fructose-Induced Non-Alcoholic Steatohepatitis with a Focus on the AMPK/Nrf2 Signaling Axis by Soha S. Zakaria, Safaa M. Hanafy

“…<i>Background and Objectives</i>: High fructose intake is associated with non-alcoholic fatty liver disease (NAFLD), a chronic liver disease that is on the rise worldwide. …”
Get full text

From gut to liver: Exploring the crosstalk between gut-liver axis and oxidative stress in metabolic dysfunction-associated steatotic liver disease by Mi Zhou, Jianyu Lv, Xinli Chen, Yujie Shi, Guanqun Chao, Shuo Zhang

“…Non-alcoholic fatty liver disease (NAFLD), now recognized as metabolic dysfunction-associated steatotic liver disease (MASLD), represents a significant and escalating global health challenge. …”
Get full text

Ketosis Onset Type 2 Diabetes Had Better Islet β-Cell Function and More Serious Insulin Resistance by Hongyun Lu, Fang Hu, Yingjuan Zeng, Lingling Zou, Shunkui Luo, Ying Sun, Hong Liu, Liao Sun

“…Our results showed that ketosis onset group had higher prevalence of nonalcoholic fatty liver disease (NAFLD) than nonketotic group (P=0.04). …”
Get full text

Potential alternative and novel biomarkers for paediatric MAFLD: exploratory evidence from a Chinese cohort by Fan Yang, Mengyuan Hu, Lulian Xu, Xiaowei Zheng, Lihong Zhu, Le Zhang, Haoyang Zhang

“…Abstract Background While the associations between pediatric non-obese metabolic dysfunction-associated fatty liver disease (MAFLD) and multiple diagnostic biomarkers are well-established, the role of a broader range of blood-based, urine-based, and body composition-based biomarkers for monitoring MAFLD are needed. …”
Get full text

Evaluating the therapeutic effect of different forms of silymarin on liver status and expression of some genes involved in fat metabolism, antioxidants and anti‐inflammatory in old... by Samira Faryadi, Ardashir Sheikhahmadi, Ayoub Farhadi, Himan Nourbakhsh

“…There were decreases in liver dry matter and fat contents, non‐alcoholic fatty liver disease and hepatocyte ballooning, and an increase in glutathione peroxidase gene expression and a decrease in iNOS gene expression in birds fed the NSM100, NSM200, LSM100 and LSM200 diets compared to the control group. …”
Get full text

Noninvasive Evaluation of Liver Function in Morbidly Obese Patients by Patrick H. Alizai, Isabella Lurje, Andreas Kroh, Sophia Schmitz, Tom Luedde, Julia Andruszkow, Ulf P. Neumann, Florian Ulmer

“…More than half of the obese patients develop nonalcoholic fatty liver disease (NAFLD), which may further progress to nonalcoholic steatohepatitis (NASH) and cirrhosis. …”
Get full text

Association between triglyceride-glucose index and clinical outcomes among patients with chronic kidney disease: a meta-analysis by Jinli Tuo, Zhong Li, Linshen Xie

“…Secondary outcomes included the coronary artery disease (CAD) mortality, CKD progression, risk of severe coronary artery stenosis (SCAS), major adverse cardiovascular event (MACE), coronary artery calcification (CAC) progression, end-stage renal disease (ESRD), and nonalcoholic fatty liver disease (NAFLD). The hazard ratio (HR) and odds ratio (OR) with 95% confidence interval (CI) were combined to assess the predictive role of TyG index for above clinical outcomes among CKD patients. …”
Get full text

Gut Microbiome Modulation in Hepatocellular Carcinoma: Preventive Role in NAFLD/NASH Progression and Potential Applications in Immunotherapy-Based Strategies by Elisa Monti, Clara Vianello, Ilaria Leoni, Giuseppe Galvani, Annalisa Lippolis, Federica D’Amico, Sara Roggiani, Claudio Stefanelli, Silvia Turroni, Francesca Fornari

“…Hepatocellular carcinoma (HCC) is a heterogeneous tumor associated with several risk factors, with non-alcoholic fatty liver disease (NAFLD) emerging as an important cause of liver tumorigenesis. …”
Get full text

Indicators Of Morbidity And Mortality From Diseases of the Digestive System in the Krasnodar Krai and the Quality of Medical Care for Gastroenterological Patients by N. V. Korochanskaya, V. M. Durleshter, O. V. Kovalevskaya, S. N. Serikova, K. I. Popandopulo

“…The frequency of viral liver lesions tends to decrease, while the proportion of liver cirrhosis in the outcome of non-alcoholic fatty liver disease (NAFLD) progressively increase, having reached 7 % in 2017–2018. …”
Get full text

Animal Models of Steatosis (NAFLD) and Steatohepatitis (NASH) Exhibit Hepatic Lobe-Specific Gelatinases Activity and Oxidative Stress by Giuseppina Palladini, Laura G. Di Pasqua, Clarissa Berardo, Veronica Siciliano, Plinio Richelmi, Stefano Perlini, Andrea Ferrigno, Mariapia Vairetti

“…This study evaluates this heterogeneity in nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) rat models. …”
Get full text